Join

Compare · AMLX vs PFE

AMLX vs PFE

Side-by-side comparison of Amylyx Pharmaceuticals Inc. (AMLX) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AMLX and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PFE is the larger of the two at $304.95B, about 270.0x AMLX ($1.13B).
  • Over the past year, AMLX is up 239.9% and PFE is up 17.1% - AMLX leads by 222.8 points.
  • PFE has been more active in the news (10 items in the past 4 weeks vs 3 for AMLX).
  • PFE has more recent analyst coverage (25 ratings vs 24 for AMLX).
PerformanceAMLX+239.92%PFE+17.13%
2025-04-28+0.00%2026-04-24
MetricAMLXPFE
Company
Amylyx Pharmaceuticals Inc.
Pfizer Inc.
Price
$17.03-1.56%
$26.98+1.20%
Market cap
$1.13B
$304.95B
1M return
+23.05%
-1.21%
1Y return
+239.92%
+17.13%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2022
News (4w)
3
10
Recent ratings
24
25
AMLX

Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

PFE

Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Latest AMLX

Latest PFE